CTRI/2013/06/003782已完成2 期
A Phase II, randomized, multi-centric, open-label, two arm study to determine the safety profile and establish the efficacy of Xprenor® (buprenorphine oral lyophilisate) in comparison with Subutex® (buprenorphine hydrochloride) in opioid dependent patients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Clinical condition: Opioid dependent patients, eligible for opioid substitution therapy.
- •2.Gender: Male or Female.
- •3. Age: 18 - 60 years (both inclusive).
- •4. BMI: 18.0 to 30.0 Kg/m2
- •5. Capable of providing voluntary informed consent.
- •6. Female patients who are sexually active will be of non-child bearing potential (i.e., surgically sterilized or postmenopausal), abstain from sexual intercourse, or use a reliable method of contraception (e.g. hormonal contraceptive, condom with spermicide, IUD) for at least 30 days prior to dosing and during the duration of the study.
排除标准
- •1.Current or previous (within previous 2 days) dependence treatment, e.g. buprenorphine or methadone.
- •2.Hypersensitivity to buprenorphine or any other component of the oral lyophilisate.
- •3.Positive urine drug test for cocaine or amphetamines at screening.
- •4.Severe hepatic insufficiency (defined as liver function tests, including alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, greater than three times the upper limit of normal).
- •5.Concomitant use of benzodiazepines, which may potentiate respiratory depression, above recommended therapeutic doses or patients who are not stabilized on benzodiazepine therapy.
- •6.Concomitant use of other central nervous system depressant, such as other opioid derivatives, certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances.
- •7.Concomitant use of monoamine oxidase inhibitors, which may aggravate opioid effects.
- •8.Administration of any approved or investigational long-acting injections of antipsychotic medications.
- •9.Current psychiatric diagnosis of major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise the patientâ??s ability to complete the study.
- •10.Female patients with a positive pregnancy test, lactating mother, women refusing to agree to adequate contraception and pregnancy tests during the study, or women who are planning to become pregnant during the period of the trial.
- •11.Participation in a clinical trial of a pharmacological agent within 6 months of screening.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000004850EUCTR2016-002529-12-SKovartis Pharma AG150
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000004850EUCTR2016-002529-12-DEovartis Pharma AG150
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHEUCTR2016-002529-12-BEovartis Pharma AG150
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000012236EUCTR2016-002529-12-ESovartis Farmacéutica, S.A.150
招募中
2 期
A trial of sodium-copper-chlorophyllin given along with treatment of physicianâ??s choice versus treatment of physicianâ??s choice in asymptomatic or mildly symptomatic patients with Covid-19CTRI/2021/02/030986IDRS Labs Private Limited